eISSN: 2300-6722
ISSN: 1899-1874
Medical Studies/Studia Medyczne
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
2/2017
vol. 33
 
Share:
Share:
abstract:
Review paper

Nalbuphine: some aspects of the research and applications

Maxim Logash
1
,
Petro Pokotylo
1
,
Bożena Zboina
2
,
Renata B. Stępień
3

  1. Department of Normal Anatomy, Lviv National Medical University‚ Danylo Halycky, Lviv, Ukraine
  2. Department of Pedagogy and Health Sciences, College of Business and Entreprise, Ostrowiec Swietokrzyski, Poland
  3. Department of Oncology and Nursing Oncology, Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland
Medical Studies/Studia Medyczne 2017; 33 (2): 146–154
Online publish date: 2017/06/30
View full text Get citation
 
PlumX metrics:
Nalbuphine hydrochloride is a synthetic, non-scheduled opioid agonist/antagonist analgesic, widely used across different branches of medicine. Despite the fact that nalbuphine has been used in the clinical setting for more than 40 years, there is still a lot of controversy regarding its mechanism of action and side-effects, including the development of the addiction to the drug. Recent data demonstrated the increase of non-medical use of nalbuphine. Moreover, in some countries it was placed in list of psychotropic and addictive substances. The increasing popularity of nalbuphine led us to review and analyse the data regarding both clinical and non-clinical applications of the drug. Furthermore, we performed an extensive analysis regarding available experimental models and approaches used in the research of opioid substances. Despite a set of problems in clinical settings due to the opioid nature of nalbuphine, it belongs to an indispensable group of analgesics for pain control.
keywords:

addiction, experimental model, nalbuphine

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.